HPLC Column Selection according to Ph. EUR.

The European Pharmacopoeia (Ph. Eur.), also known as the European Pharmacopoeia, sets standards and requirements for medicines and pharmaceutical products in Europe and is the reference work for quality control. It serves to harmonize national regulations for the manufacture and distribution of medicines and other pharmaceutical products.

Ph. Eur. and HPLC Columns

The requirements for column material, particle size, surface chemistry, and other important parameters affecting separation performance are specified. The specific tests and procedures for the characterization and testing of HPLC columns are described in the respective chapters of the pharmacopoeia.

HPLC columns that comply with the standards of the European Pharmacopoeia are used in various pharmaceutical applications, including drug analysis, purity determination, identification of impurities, and quantitative analysis in drug development and manufacturing.

The following list contains HPLC columns suitable for pharmacopoeial requirements. Please contact us with any questions - we are happy to help our customers find the suitable HPLC column.


Overview of HPLC Columns according to Pharmacopoeia Ph. EUR.


Pharmaceutical Substance
with Monograph Number
Reagent
Code Number
Recommended
Column Type
Suitable
Columns
Column Dimensions Description

  • Abacavir sulfate (2589)
  • Tadalafil (2606)
  • Zolmitriptan (2737)
  • Fulvestrant (2443)

1171700

Daicel Chiralpak AD

CHIRALPAK AD
250 x 4,6 mm, 10 µm

  • l = 250mm, 4.6mm, 10µm
    (Abacavir sulfate, Tadalafil)
  • l = 250mm, 4.6mm, 5µm
    (Fulvestrant, Zolmitriptan)

Silica gel AD for separation of chiral components, RP 5µm. Coated with substituted amylose.

  • Lamivudine (2217)
  • Voriconazole (2576)
  • Fexofenadine hydrochloride (2280)
  • Glycopyrronium bromide (1783)

1161300

Merck Chiradex

ChiraDex, 5µm, Hibar RT 250 x 4,6mm


  • l = 250mm, 4.6mm, 5µm
    (Fexofenadine Hydrochloride,
    Lamivudine, Voriconazole)
  • l = 250mm, 4mm, 5µm
    (Glycopyrronium bromide)

Silica gel BC for separation of chiral components, RP 5µm. Coated with ß-Cyclodextrin.

  • Valacyclovir hydrochloride (1768)

1192400

Daicel Crownpak CR(+)

CROWNPAK CR(+)
150 x 4 mm, 5 µm

  • l = 150mm, 4mm, 5µm

Silica gel CR+ for separation of chiral components. RP. Coated with crown ether.

1176900

GL-Sciences InertSustainSwift C18

Silica gel. Alkylated, silanized RP with endcapping. Chemically modified by introduction of alkyl groups to be suitable for strongly aqueous mobile phases.

  • Estradiol valerate (1614)

HALO C18

HALO C18, 90 Å
2,7 µm, 4,6 x 100 mm

  • l = 100mm, 4.6mm, 2,60µm
    or 2.7µm

Silica gel AD for separation of chiral components, RP 5µm. Coated with substituted amylose.

  • Atorvastatin calcium trihydrate (2191)
  • Dexchlorpheniramine maleate (1196)

1109800

Daicel Chiralpak IA

CHIRALPAK IA-10 SFC
250 x 4,6 mm, 10 µm

Very fine silica gel (10µm) whose surface is chemically modified by introduction of amylose groups. RP.

  • Aminic acid (2809)
  • Phenytoin (1253)
  • Nicorandil (2332)
  • Indapamide (1108)
  • Cimetidine (0756)
  • Benzocaine (0011)
  • Aprepitant (2757)

1188400

HALO AQ-C18

HALO AQ-C18, 90 Å
5 µm, 4,6 x 250 mm


HALO AQ-C18, 90 Å
2,7 µm, 4,6 x 100 mm

  • l = 250mm, 4.6mm, 4µm
    (Aminic acid)
  • l = 250mm, 4.6mm, 5µm
    (Phenytoin, Nicorandil,
    Cimetidine, Aprepitant)
  • l = 200mm, 4.6mm, 5µm
    (Indapamide)
  • l =100mm, 4.6mm, 3µm
    (Benzocaine)

Very fine silica gel with bonded octadecylsilyl groups, suitable for use with strongly aqueous mobile phases, including 100% aqueous phases.

  • Clomipramine hydrochloride (0889)


1194200

GL-Sciences InertSustain Cyano

InertSustain Cyano 100Å
5µm, 4,6 x 250mm

  • l = 250mm, 4.6mm, 5µm

Very fine silica gel, pretreated by growing and hydrolysing most of the surface siloxane bridges before grafting the cyanopropylsilyl groups.

  • Dronedarone hydrochloride (3039)
  • Paclitaxel (1794)
  • Tenoxicam (1156)

1168100


Zorbax StableBond CN

ZORBAX StableBond SB-C8 80 Å
5 µm, 4,6 x 250 mm

  • l = 250mm, 4.6mm, 5µm
  • l = 150mm, 4.6mm, 3.5µm
    (Tenoxicam)

Very fine silica gel, whose surface is chemically modified by introduction of diisobutyloctadecylsilyl groups.

  • Aprotinin (0580)
  • Anaparoid sodium (2090)
  • Etanercept (2895)
  • Teriparatide (2829)

1077200

HALO HILIC

  • l = 150mm, 4.6mm, 3.5µm (Teriparatide)
  • l = 75mm, 7.5mm, 10µm (Aprotinin)
  • l = 250mm, 4.6mm, 5µm (Etanercept)

Very fine, surface-modified silica gel with hydrophilic properties.

  • Benzalkonium chloride (0372)

1174500

GL-Sciences InertSustain Cyano

InertSustain Cyano 100Å
5µm, 4,6 x 250mm

  • l = 250mm, 4.6mm, 5µm

Very fine silica gel, the surface of which is chemically modified by the introduction of cyanopropylsilyl groups. Cyanopropylsilylated, post-silanized RP.

  • Akebia sprout (2472)
  • White horehound (1835)
  • Arnica Tincture (1819)
  • Acemetacin (1686)
  • Adenosine (1486)
  • Albendazole (1386)
  • Alfadex (1487)
  • Amikacin (1289)
  • Aceclofenac (1281)

1115400



Chromanik Sunniest C18

Sunniest, C18, 120 Å
5 µm, 4,6 x 250 mm

  • l = 250mm, 4.6mm, 5µm
    (Akebia sprout, Aceclofenac,
    Adenosine, Albendazole, Amikacin)
  • l = 250mm, 4mm, 5µm
    (White horehound, Acemetacin)
  • l = 120mm, 4mm, 5µm (Arnica tincture)
  • l = 250mm, 4.6mm, 10µm (Alfadex)

Very fine silica gel, the surface of which is chemically modified by the introduction of octadecylsilyl groups. Octadecylsilylated, post-silanized RP.

  • Cowhage root (2434)
  • Primidone (0584)
  • Raltegravir potassium
    chewable tablets (2939)
  • Norepinephrine hydrochloride (0732)

1154500

Merck Chromolith Performance
RP-18e

Validation Kit Chromolith
Performance RP-18
endcapped 100 x 4,6mm

  • l = 100mm, 4.6mm
    (Cowhage root, Primidone,
    Norepinephrine hydrochloride)
  • l = 250mm, 4.6mm, 5µm
    (Raltegravir chewable tablets)

Monolithic rods made of highly porous (over 80%), metal-free quartz with bimodal pore structure and a surface chemically modified by the introduction of octadecylsilyl groups.

  • Andrographis herb (2712)
  • Altizide (2185)
  • Diprophylline (0486)
  • Propyl gallate (1039)
  • Vincamine (1800)

1177900



HALO AQ-C18

ALO AQ-C18, 90 Å
5 µm, 4,6 x 100 mm

  • l = 250mm, 4.6mm, 5µm
    (Andrographis herb, Vincamine)
  • l = 150mm, 3.9mm
    (Altizide, Diprophylline)
  • l = 100mm, 4.6mm, 3.5µm
    (Propyl gallate)

Silica gel for chromatography, octadecylsilyl, with embedded polar groups, with end-caps; the particles are based on a mixture of silica modified on the surface by bonding octadecylsilyl groups chemically and silica modified with a reagent that yields a surface with chains containing embedded polar groups.

1165100

ACE C18-Amide

 

Very fine silica gel, the surface of which is chemically modified by the introduction of polar groups and terminal octadecyl groups.

  • Alfacalcidol (1286)
  • Gabapentin (2173)
  • Nicergoline (1998)
  • Sulfadimethoxine (2741)

1190500

Waters Acquity BEH C18

 

  • l = 250mm, 4.6mm, 5µm
    (Sulfadimethoxine, Gabapentin)
  • l = 150mm, 4.6mm 3.5µm (Nicergoline)
  • l = 150mm, 4.6mm, 1.7µm (Alfacalcidol)

Synthetic, spherical, ethane-1,2-diyl-bridged hybrid particles containing both inorganic (silica) and organic (organosiloxane) components and whose surface is chemically modified by the introduction of octadecylsilyl groups.

  • Everolimus (2918)
  • Indometacin (0092)
  • Paracetamol (0049)
  • Protamine sulfate (0569)

1193900

ACE UltraCore Super C18

 

  • l = 150mm, 2.1mm, 2.7µm (Everolimus)
  • l = 150mm, 4.6mm, 3.6µm (Protamine sulfate)
  • l = 100mm, 4.6mm, 2.7µm (Paracetamol)
  • l = 100mm, 4.6mm, 2.6µm (Indometacin)

Silica gel with spherical silica dioxide particles consisting of a non-porous, solid silica dioxide core surrounded by a thin, porous, octadecylsilylated silica dioxide layer.

  • Ergometrine meleate (0223)
  • Ucaria branches with thorns
    (2729)

1196700

Kromasil EternityXT C18

Kromasil EternityXT-10-C18
4,6 x 100 mm


Kromasil EternityXT-10-C18
4,6 x 150 mm

  • l = 100mm, 4.6mm, 3.5µm
    (Ergometrine meleate)
  • l = 150mm, 4.6mm, 5µm
    (Ucaria branches with thorns)

Very fine silica gel, the surface of which is chemically modified by the introduction of octadecylsilyl groups, which are resistant to bases up to a pH of 11.

  • Fluorescein (2348)
  • Formoterol fumarate dihydrate (1724)

1155200

Zorbax StableBond C8

ZORBAX StableBond SB-C8, 80Å
5 µm, 4,6 x 250 mm


ZORBAX StableBond SB-C8, 80Å
5 µm, 4,6 x 150 mm

  • l = 250mm, 4.6mm, 5µm (Fluorescein)
  • l = 150, 4.6, 5µm
    (Formoterol fumarate dihydrate)

Highly pure, very fine silica gel, the surface of which is chemically modified by the introduction of octylsilyl groups and sterically protected by attachment of branched hydrocarbons to the silanes.

  • Boldin (2971)
  • Lacosamide (2992)
  • Lacosamide Infusion (2991)
  • Nortriptyline hydrochloride (0941)
  • Rotigotine (3014)

1200900

GL Sciences InertSustain C8

InertSustain C8 100Å
5µm, 4,6 x 250mm


InertSustain C8, 100Å
3,5 µm, 4,6 x 150 mm


InertSustain C8 100Å
5µm, 4,6 x 150mm

  • l = 250mm, 4.6mm, 5µm (Boldin)
  • l = 150mm, 4.6mm, 3.5µm
    (Lacosamide)
  • l = 150mm, 4.6mm, 5µm
    (Lacosamide infusion, Nortriptyline hydrochloride, Rotigotine)

Very fine silica gel, the surface of which is chemically modified by the introduction of densely linked octylsilyl groups.

  • Ketobemidone hydrochloride (1746)
  • Oxcarbezepine (2577)

1153900

GL Sciences InertSustain
PhenylHexyl

InertSustain Phenylhexyl 100Å
5µm, 4,6 x 250mm

  • l = 250mm, 4.6mm, 5µm

Very fine silica gel, the surface of which is chemically modified by the introduction of phenylhexylsilyl groups.

  • Donepezil hydrochloride (2582)
  • Gadobutrol monohydrate (2735)
  • Valacyclovir hydrochloride (1768)
  • Zoledronic acid monohydrate (2743)

1170600

GL Sciences InertSustain
PhenylHexyl

InertSustain Phenylhexyl 100Å
3µm, 4,6 x 250mm


InertSustain Phenylhexyl 100Å
3µm, 4,6 x 150mm

  • l = 250mm, 4.6mm, 5µm
    (Zoledronic acid monohydrate, Valacyclovir hydrochloride)
  • l = 250mm, 4.6mm,3µm
    (Gadobutrol monohydrate)
  • l = 150mm, 4.6mm, 3µm
    (Donepezil hydrochloride)

Silica gel for chromatography, phenylhexylsilylated, reconditioned R. Very fine silica gel, the surface of which is chemically modified by the introduction of phenylhexylsilyl groups.

  • Pholcodine monohydrate (0522)
  • Testosterone (1373)
  • Vigabatrin (2305)
  • Zolmitriptan (2737)

1198900

ACE UltraCore
SuperPhenylHexyl

ACE Ultracore 2,5
Superphenylhexyl 75 x 4,6mm


ACE Ultracore 2,5
Superphenylhexyl 100 x 4,6mm


ACE Ultracore 2,5
Superphenylhexyl 100 x 3,0mm

  • l = 7.5mm, 4.6mm, 2.6µm
    (Pholcodine monohydrate)
  • l = 100mm, 4.6mm, 2.7µm
    (Testosterone, Vigabatrin)
  • l = 100mm, 3mm, 2.7µm
    (Zolmitriptan)

Silica gel with spherical silica dioxide particles consisting of a non-porous, solid silica dioxide core surrounded by a thin, porous, phenylhexylsilylated silica dioxide layer.

  • Adapalene (2445)
  • Celecoxib (2591)
  • Mitomycin (1655)
  • Probenecid (0243)

1075700

Zorbax StableBond Phenyl

ZORBAX StableBond SB-C8, 80Å, 5 µm
4.6 x 250 mm, cartridge (AC)

  • l = 250mm, 4.6mm, 5µm
    (Adapalene, Celecoxib, Probenecid)
  • l = 300mm, 3.9mm, 10µm
    (Mitomycin)

Silica gel for chromatography, phenylsilylated, R1 spherical silica; pore size: 80 Å; surface area: 180 m2/g; C load: 5.5%.

  • Adapalene (2445)
  • Celecoxib (2591)
  • Mitomycin (1655)
  • Probenecid (0243)

1154900

Waters XTerra Phenyl

XTerra Phenyl 5µm 4.6x250mm

  • l = 250mm, 4.6mm, 5µm
    (Adapalene, Celecoxib, Probenecid)
  • l = 300mm, 3.9mm, 10µm (Mitomycin)

Very fine silica gel, the surface of which is chemically modified by the introduction of phenyl groups. To minimize interactions with basic compounds, it is carefully end-capped, covering most of the remaining silanol groups.

  • Capsicum (1859)
  • mepyramine maleate (0278)
  • moxifloxacin hydrochloride (2254)

1197900

GL Sciences InertSustain Phenyl

InertSustain Phenyl 100Å
5µm, 4.6 x 250mm

  • l = 250mm, 4.6mm, 5µm
    (Capsicum,
    Mepyramine maleate, Moxifloxacin hydrochloride)

Very fine silica gel, largely freed from siloxane bridges on the surface by washing and hydrolysis prior to introduction of phenylsilyl groups, and chemically modified by introduction of phenyl groups.

  • Fentanyl (1210)
  • Fentanyl citrate (1103)
  • Indometacin (0092)

1200700

Waters XTerra Phenyl

XTerra Phenyl 3.5µm
2.1 x 150mm


XTerra Phenyl 3.5µm
2.1 x 100mm

  • l = 150mm, 2.1mm, 1.7µm (Fentanyl,
    Fentanyl citrate)
  • l = 100mm, 2.1mm, 1.7µm (Indometacin)

Synthetic, spherical, ethan-1,2-diyl-bridged hybrid particles containing both inorganic (silicon dioxide) and organic (organosiloxane) components, and chemically modified by introduction of phenylsilyl groups on the surface.

  • Acetazolamide (0454)
  • Senna Leaftet (0206)

1174600

ES Industries Sync Polar RP

  • l = 150mm, 3mm, 5µm (Acetazolamide)
  • l = 250mm, 4.6mm, 4µm
    (Senna leaflet)

Very fine silica gel, the surface of which is chemically modified by introduction of propoxyphenyl groups.

  • Clonidine hydrochloride (0477)
  • Tiotropium bromide Monohydrate (2420)

1170700

Zorbax StableBond C3

ZORBAX StableBond SB-C8, 80Å
5 µm, 4.6 x 150 mm

  • l = 150mm, 4.6mm, 4µm
    (Clonidine hydrochloride)
  • l = 150mm, 3mm, 3.5µm
    (Senna leaflet)

Very fine silica gel, the surface of which is chemically modified by introduction of propylsilyl groups.

1077800

Macherey-Nagel Nucleosil SB

Silica gel anion exchanger, RP. Very fine silica gel whose surface is chemically modified by introduction of quaternary ammonium groups.

  • Aprotinin (0580)
  • Dibrompropamidine diisetionate
    (2300)
  • Ganciclovir (1752)
  • Metformin hydrochloride (0931)

1161400

Macherey-Nagel Nucleosil SA

EC 250/4,6 NUCLEOSIL 100-5 SA

EC 250/4,6 NUCLEOSIL 100-10 SA

  • l = 75mm, 7.5mm, 10µm
    (Aprotinin)
  • l = 250mm, 4.6mm, 5µm
    (Dibrompropamidine diisetionate)
  • l = 250mm, 4.6mm, 10µm
    (Ganciclovir, Metformin hydrochloride)

Silica gel for exclusion chromatography. Very fine silica gel (10µm) with a hydrophilic surface. The average pore size is about 30nm. The substance, which can be used in aqueous solutions with a pH between 2 and 8 and in organic solvents, is for the separation of proteins with a relative molecular mass of 1,000 to 300,000.

  • Anti-T-lymphocyte immoglobulin
    from animals for use in humans (1928)

1077900

Shodex Protein KW-803 8

  • l = 60mm, 7.5mm
    (Capsicum, Mepyramine maleate;
    Moxifloxacin hydrochloride)

Silica gel for exclusion chromatography. Very fine silica gel (10µm) with a hydrophilic surface. The average pore size is about 30nm. The substance, which can be used in aqueous solutions with a pH between 2 and 8 and in organic solvents, is for the separation of proteins with a relative molecular mass of 1,000 to 300,000.

  • Levetiracetam (2535)
  • Levodropropizine (1535)
  • Oxaliplatin (2017)
  • Rotigotine (3014)
  • Timolomaleate (0572)
  • Vasartrtan (2423)

1110300

Daicel Chiralcel OD

CHIRALCEL® OD, 250 x 4,6 mm, 10 µm

  • l = 250mm, 4.6mm, 10µm
    (Levetiracetam, Levodropropizine,
    Oxaliplatin, Rotigotine)
  • l = 250mm, 4.6mm, 5µm
    (Timololmaleate, Vasartrtan)

Silica gel-cellulose derivative for separation of chiral components.

1144200

XBridge BEH C18

Polymer, silicon organic, amorphous, octadecylsilylated R. Synthetic, spherical hybrid particles containing both inorganic (silicon dioxide) and organic (organosiloxane) components. The surface is modified by introduction of 3-fold bonded octadecylsilyl groups.

  • Azithromycin (1649)
  • Goserelin (1636)
  • Ibuprofen(0721)
  • Imatinib mesylate (2736)
  • Mesalazine (1699)
  • Tetracaine (2909)

1164900

XBridge BEH C18

Xbridge C18 250 mm
4,6 mm 5 µm 135 Å


XBridge C18, 130Å,
3,5µm 4,6 x 150mm

  • l = 250mm, 4.6mm, 5µm (Azithromycin,
    Mesalazine)
  • l = 150mm, 4.6mm, 3.5µm (Goserelin)
  • l = 150mm, 4.6mm, 5µm (Ibuprofen)
  • l = 150mm, 3mm, 3.5µm (Imatinib mesylate)
  • l = 150mm, 4.6mm (Tetracaine)

Synthetic, spherical hybrid particles containing both inorganic (silicon dioxide) and organic (organosiloxane) components and chemically modified surface by introduction of octadecylsilyl groups.

  • Zanamivir (2611)

1191500

Shodex Asahipak NH2P-50

Asahipak NH2P-50 4E, 100 Å
5 µm, 4,6 x 250 mm

  • l = 250mm, 4.6mm, 5µm

Vinyl polymer, aminoalkylated RP Spherical particles (5µm) of a vinyl alcohol copolymer whose surface is chemically modified by introduction of aminoalkyl groups.

  • Formoterol fumarate dihydrate (1724)

1155400

Shodex Asahipak ODP-50

  • l = 150mm, 4.6mm

Vinyl polymer, octadecylated RP. Spherical particles (5µm) of a vinyl alcohol copolymer whose surface is chemically modified by introduction of octadecyl groups bonded to the hydroxyl groups.

  • Azithromycin (1649)
  • Pefloxacin mesilate dihydrate (1460)

1121600

Shodex Asahipak ODP-50

Asahipak ODP-50 4E, 250 Å
5 µm, 4.6 x 250 mm


Asahipak ODP-50 6D
250 Å, 5 µm, 6 x 150 mm

  • l = 250mm, 4.6mm, 5µm (Azithromycin)
  • l = 150mm, 6mm, 5µm
    (Pefloxacin mesilate dihydrate)

Vinyl polymer, octadecylsilylated RP. Spherical particles of a vinyl alcohol copolymer (5µm), to which octadecylsilane is bound.

  • Malic acid (2080)
  • Olsalazine sodium (1457)
  • Teriparatide (2829)

1131000

Sepax Carbomix H

  • l = 300mm, 7.8mm, 9µm (Malic acid)
  • l = 250mm, 9mm (Olsalazine sodium)
  • l = 250mm, 9mm, 7.5µm

Ion exchanger. Exchange resin with sulfonic acid groups fixed to a framework of polystyrene crosslinked with divinylbenzene.

  • Galactose (1215)

1156800

Shodex SUGAR SH1011

SUGAR SH1011, 6 µm, 8 x 300 mm

  • l = 300mm, 6.5mm, 10µm

Strong cation exchanger resin in protonated form with sulfonic acid groups fixed to a framework of polystyrene crosslinked with divinylbenzene.

  • Acamprosate calcium (1583)
  • Aspartic acid (0797)
  • Erythritol (1803)
  • Magaldrate (1539)
  • Magnesium aspartate dihydrate (1445)

1016700

Sepax Carbomix H

Carbomix H-NP5, 8% Crosslinkage,
5 µm, 4.6 x 150 mm


Carbomix H-NP10, 8% Crosslinkage,
10 µm, NP 7.8 x 300 mm

  • l = 150mm, 4.6mm, 5µm (Acamprosate calcium)
  • l = 300mm, 7.8mm, 9µm (Aspartic acid,
    Magnesium aspartate dihydrate)
  • l= 300mm, 8mm, 9µm (Erythritol)

Cation exchanger resin in protonated form. The resin is in the form of beads. The exchanger contains sulfonic acid groups fixed to a framework of polystyrene crosslinked with 8% divinylbenzene.

  • Galactose (1215)
  • Glucose (0177)
  • Myo-inositol (1805)
  • Isomalt (1531)
  • Maltitol (1235)
  • Mannitol (0559)
  • Sorbitol (0435)

1104600

Sepax Carbomix Ca

Carbomix Ca-NP10, 5% Crosslinkage, 10 µm
NP 7.8 x 300 mm

  • l = 300mm, 6.5mm, 10µm (Galactose)
  • l = 300mm, 7.8mm, 9µm
    (Glucose, Myo-inositol, Isomalt,
    Maltitol, Mannitol, Sorbitol)

Cation exchanger, calcium salt, strongly acidic RP. Exchange resin with sulfonic acid groups fixed to a polymer framework consisting of polystyrene crosslinked with 5% divinylbenzene.

  • Trehalose dihydrate (2297)

1176100

Shodex SUGAR KS-801 to 806

SUGAR KS-801, Na+, 6 µm, 8 x 300 mm

SUGAR KS-802, Na+, 6 µm, 8 x 300 mm <

SUGAR KS-803, Na+, 6 µm, 8 x 300 mm

  • l = 300mm, 8mm, 6µm

Cation exchanger, sodium salt, strongly acidic RP. Exchange resin with sulfonic acid groups fixed to a polymer framework consisting of polystyrene crosslinked with divinylbenzene.


Permissible Deviations according to Ph. Eur.

The Ph. Eur. allows deviations in the dimensions of HPLC columns in the respective methods. This provides the user of classical HPLC with generous flexibility to optimize the method for their conditions without requiring revalidation of the entire method.
If adjustments to the parameters are made within the permissible limits, demonstrating system suitability is sufficient, and revalidation of the modified method is not required. The primary aim of an adjustment is generally to optimize a method to meet system suitability requirements.

According to current regulations (Ph. Eur. General Chapter 2.2.46), the following modifications are permissible:


Property Gradient Elution Isocratic Elution

Column Length

± 70 %

± 70 %

Particle Size

no adjustment allowed

Reduction by max. 50%; enlargement not allowed

Inner Diameter

± 25 %

± 25 %

Flow Rate

adjustment possible with change in column dimensions

± 50% (exceedance allowed if column dimensions are changed)

Column Temperature

± 5 °C (if working temperature specified and nothing else prescribed)

± 10 °C (if working temperature specified and nothing else prescribed)

Injection Volume

Reduction possible (provided detection and repeatability of the peak(s) to be determined are satisfactory); larger injection volume not allowed

Reduction possible (provided detection and repeatability of the peak(s) to be determined are satisfactory), larger injection volume not allowed

pH Value of the Mobile Phase

no adjustment allowed

± 0.2 pH units, unless otherwise prescribed;
± 1.0 pH units if testing non-ionizable substances

Salt Concentration of Buffer

no adjustment allowed

± 10 %

Composition of Mobile Phase

Minor changes under following conditions:

  • System suitability requirements are met
  • Main peak(s) within ± 15 % of specified retention time(s)
  • The mobile phase does not have weaker eluting strength in its final composition than in the prescribed composition

<± 30 % (rel.) or ± 2 % (abs.) for quantity of least abundant component; no other component may be changed by more than 10 % (abs.)